ReviewInternational journal of molecular sciences2015
Circulating Cell-Free Tumour DNA in the Management of Cancer.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05131243 (the Role of ctDNA in Predicting the Recurrence Risk of Stage Ⅱ and Ⅲ Colorectal Cancer and the Dynamic Changes in ctDNA of Patients With Adjuvant Chemotherapy), which is not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
the Role of ctDNA in Predicting the Recurrence Risk of Stage Ⅱ and Ⅲ Colorectal Cancer and the Dynamic Changes in ctDNA of Patients With Adjuvant Chemotherapy
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.The oncologist · 2017Pooled it
- Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Circulating Tumor DNA in Cholangiocarcinoma: A Precision Oncology Roadmap.Cancer management and research · 2026Review
- Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer.Breast cancer research : BCR · 2025Article
- Application of Liquid Biopsy Technology in Lung Cancer: A Bibliometric Study and Visualization Analysis.Cancer management and research · 2025Review
- Review
- Language model enables end-to-end accurate detection of cancer from cell-free DNA.Briefings in bioinformatics · 2024Article
- Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.Annals of surgical oncology · 2023Article
- Molecular and clonal evolutioniScience · 2023Article
- Intratumoral Heterogeneity in Lung Cancer.Cancers · 2023Review
- Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.BMC cancer · 2023Article
- Liquid biopsy and tumor DNA/RNA detection in the cerebrospinal fluid of patients diagnosed with central nervous system glioma - A review article.Surgical neurology international · 2023Review
- Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers.Clinical epigenetics · 2022Article
- Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin.Cancer gene therapy · 2022Article
- Review
- Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer.Journal of oncology · 2022Article
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis.Translational oncology · 2021Review
- Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of new sensitive molecular techniques, circulating cell-free tumour DNA containing mutations can be identified in the plasma of cancer patients. The applications of this technology may result in significant changes to the care and management of cancer patients. Whilst, currently, these "liquid biopsies" are used to supplement the histological diagnosis of cancer and metastatic disease, in the future these assays may replace the need for invasive procedures. Applications include the monitoring of tumour burden, the monitoring of minimal residual disease, monitoring of tumour heterogeneity, monitoring of molecular resistance and early diagnosis of tumours and metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.